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Hospital-acquired infections with Staphylococcus au-
reus, especially methicillin-resistant S. aureus (MRSA) in-
fections, are a major cause of illness and death and impose 
serious economic costs on patients and hospitals. However, 
the recent magnitude and trend of these infections have not 
been reported. We used national hospitalization and resis-
tance data to estimate the annual number of hospitalizations 
and deaths associated with S. aureus and MRSA from 1999 
through 2005. During this period, the estimated number 
of S. aureus–related hospitalizations increased 62%, from 
294,570 to 477,927, and the estimated number of MRSA-
related hospitalizations more than doubled, from 127,036 
to 278,203. Our ﬁ  ndings suggest that S. aureus and MRSA 
should be considered a national priority for disease control.
S
taphylococcus aureus is a leading cause of hospital-ac-
quired infections. It is the primary cause of lower re-
spiratory tract infections and surgical site infections (1,2) 
and the second leading cause of nosocomial bacteremia (3), 
pneumonia, and cardiovascular infections (1,2). Infections 
with S. aureus are especially difﬁ  cult to treat because of 
evolved resistance to antimicrobial drugs. Resistance to 
penicillin and newer narrow-spectrum β-lactamase–resis-
tant penicillin antimicrobial drugs (e.g., methicillin, oxacil-
lin) appeared soon after they were introduced into clinical 
practice in the 1940s and 1960s, respectively (4). Penicillin 
resistance was initially conﬁ  ned to a small number of hos-
pitalized patients, but resistance spread as use of penicillin 
increased, ﬁ  rst to other hospitals and then into the commu-
nity (5). By the late 1960s, >80% of community- and hos-
pital-acquired S. aureus isolates were resistant to penicillin 
(4). Recent reports suggest that the evolution and spread of 
methicillin-resistant S. aureus (MRSA) seems to be follow-
ing a similar wavelike emergence pattern (5).
MRSA is now endemic, and even epidemic, in many 
US hospitals, long-term care facilities (6), and communities 
(7,8). Contrary to the generally accepted view, community-
associated MRSA strains may be spreading into the health-
care system rather than the other way around (9). Data from 
the National Nosocomial Infections Surveillance system 
suggest that in intensive care units the proportion of S. au-
reus isolates that are resistant to methicillin has increased 
to 59.5%–64.4% (10,11). Recent reports also suggest that 
community-associated MRSA infections have become the 
dominant cause of community-associated S. aureus skin 
and soft tissue infections (9,12). An understanding of the 
magnitude of the problem requires accurate national esti-
mates of incidence. However, national studies examining 
the effect of S. aureus or MRSA on the healthcare system 
are >5 years old (13,14). For 2000–2001, Noskin et al. es-
timated that there were 290,000 S. aureus-related hospital-
izations (14). Kuehnert et al. estimated a similar number of 
S. aureus–related hospitalizations for 1999–2000 and re-
ported that 43.2% (125,969) were likely resistant to methi-
cillin (13).
In this study, we estimated the magnitude of the effect 
and trend in the incidence and associated mortality rates 
of infections related to S. aureus and MRSA over a 7-year 
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period, from 1999 through 2005, paying particular atten-
tion to the overall S. aureus infection level and the trend 
of typical community-associated infections. Evidence on 
the magnitude and trend of the problem on a national level 
informs rational, evidence-based decisions about how to 
allocate resources and adjust healthcare policy to address 
this issue. Infection trends are useful to clinicians, hospi-
tal administrators, insurers, and policymakers who make 
decisions regarding control measures, especially infection-
control measures to contain the spread of nosocomial and 
community-associated pathogens.
Methods
Our analysis focused on the period 1999–2005 and fol-
lowed an approach similar to that described by Kuehnert 
et al. (13). Estimated incidence of S. aureus was based on 
hospitalizations with S. aureus–related discharge diagno-
ses from the National Hospital Discharge Survey (NHDS). 
The NHDS covers ≈270,000 patients and 500 short-stay 
hospitals by using a stratiﬁ  ed, multistage survey to create 
a nationally representative annual sample of discharge re-
cords. Children and general hospitals are included; federal, 
military, Veterans Affairs, or institutional hospitals are 
not included. Each discharge record contains <7 different 
International Classiﬁ   cation of Diseases, Ninth Revision 
(ICD-9), Clinical Modiﬁ  cation, discharge diagnosis codes 
and is population weighted on the basis of the probabil-
ity of sample selection and adjusted for nonresponse. All 
acute-care hospitalizations, excluding those of infants born 
in the hospital, were considered.
S. aureus–related discharges were included if any of 
the 7 diagnosis codes contained speciﬁ  c S. aureus infection 
codes: 038.11 (S. aureus septicemias), 482.41 (S. aureus 
pneumonias), and 041.11 (other S. aureus infections). Re-
cords that contained multiple S. aureus–related discharge 
codes were only counted once, with septicemia preferen-
tially included, followed by S. aureus–related pneumonia.
Because there is no MRSA-speciﬁ  c ICD-9 code, we 
indirectly estimated the proportion of S.  aureus–related 
infections that were methicillin resistant by using antimi-
crobial drug testing data from The Surveillance Network 
(TSN) Database-USA (Focus Diagnostics, Herndon, VA, 
USA). TSN is an electronic repository of susceptibility test 
results collected from >300 microbiology laboratories in 
the United States; it has been used extensively to evalu-
ate antimicrobial drug resistance patterns and trends (15). 
Participating laboratories are geographically dispersed and 
make up a nationally representative sample on the basis of 
hospital bed size and patient population. Patient isolates are 
tested for susceptibility to several different antimicrobial 
agents on site as part of routine diagnostic testing by using 
standards established by the National Committee for Clini-
cal Laboratory Standards (NCCLS) and approved by the 
US Food and Drug Administration (15). Results are ﬁ  ltered 
to remove repeat isolates and identify microbiologically 
atypical results for conﬁ  rmation or veriﬁ  cation before be-
ing included.
We included S. aureus isolates from inpatient areas 
that were tested for susceptibility to oxacillin (which is 
used as a proxy for all β-lactam antimicrobial drugs, in-
cluding methicillin) and classiﬁ  ed as susceptible, interme-
diate, or resistant according to NCCLS breakpoint criteria. 
Data included >65,000 isolates annually, of which <0.01% 
had intermediate resistance and so were classiﬁ  ed suscep-
tible. To ensure comparability with NHDS data, isolates 
were stratiﬁ  ed by the type of infection (i.e., isolates from 
the lungs were classiﬁ  ed as pneumonias; those from the 
blood, as septicemias or bacteremias) and geographic re-
gion based on the US Census Bureau regions.
The annual estimated number of S. aureus–related 
hospitalizations was obtained from NHDS. The total 
number of MRSA-related hospitalizations was estimated 
by multiplying the number of S. aureus–related infections 
by the estimated percentage of S.  aureus isolates that 
were resistant, stratiﬁ  ed by infection type and region. Fre-
quencies of primary and secondary diagnoses were also 
extracted for all hospitalizations that included S. aureus–
related infections.
Relative standard errors for incidence of S. aureus 
were calculated by following guidelines for NHDS ac-
curacy described by Dennison and Pokras (16). Standard 
errors and 95% conﬁ  dence intervals (CIs) were calculated 
by multiplying the relative standard error by the estimated 
incidence. CIs for TSN data were calculated by using the 
Wilson score method and incorporating continuity correc-
tion as detailed by Newcombe (17). The variance of MRSA 
incidence was estimated by using the method described by 
Barnett (18) and Goodman (19).
NHDS reports whether or not hospitalization results 
in patient death but does not specify the cause of death. 
Because the primary diagnosis suggests that the disease 
played a role in patient death, we estimated the number of 
S. aureus–related deaths where the primary diagnosis code 
was an S. aureus–related code. We used the same proce-
dure as described above to determine the estimated number 
of deaths for which MRSA was involved.
Results
From 1999 through 2005, annual hospital discharges in 
the United States increased ≈8%, from 32.1 million to 34.7 
million. During this period, the estimated number of hospi-
talizations involving S. aureus–related infections increased 
62%, from 294,570 (95% CI 257,304–331,836) to 477,927 
(95% CI 421,665–534,189). S. aureus–related hospitaliza-
tions with diagnosis codes for septicemia and pneumonia 
increased 38% and 7%, respectively, and hospitalizations 
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involving other S. aureus–related infections in conditions 
classiﬁ  ed elsewhere nearly doubled. Overall, the rate of 
S. aureus–related diagnoses per 1,000 hospitalizations in-
creased 50%, from 9.17 to 13.79 (Table 1).
From 1999 through 2005, estimated MRSA-related 
hospitalizations more than doubled, from 127,036 (95% CI 
112,356–141,716) to 278,203 (95% CI 252,788–303,619). 
MRSA-related hospitalizations with a diagnosis code for 
septicemia increased 81.2%, from 31,044 (95% CI 25,170–
36,918) to 56,248 (95% CI 46,830–65,665), and MRSA-re-
lated hospitalizations with a diagnosis code for pneumonia 
increased 19.3%, from 30,632 (95% CI 24,597–36,666) to 
36,540 (95% CI 29,527–43,554). The largest increase in 
MRSA-related hospitalizations involved infections outside 
the lungs or blood; these almost tripled from 65,361 (95% 
CI 55,801–74,920) to 185,415 (95% CI 162,102–208,728). 
Overall, the rate of MRSA-related discharges per 1,000 
hospitalizations more than doubled, from 3.95 to 8.02 (Fig-
ure 1).
In hospitalizations for which S. aureus–related septice-
mia and pneumonia were listed as any 1 of the 7 discharge 
diagnoses, these diagnoses were coded as the primary di-
agnosis, on average, in 38% (standard deviation 6.4%) and 
54% (3.7%) of records, respectively, over the 7-year pe-
riod. The most frequent primary diagnosis associated with 
other S. aureus–related infections was other cellulitis and 
abscess (ICD-9 682), followed by postoperative infection 
(ICD-9 998.59), infections from an implanted device or 
graft (ICD-9 996), osteomyelitis (ICD-9 730), and diabe-
tes mellitus (ICD-9 250). Cellulitis infections increased 
>25% per year from 22,451 (95% CI 17,007–27,895) to 
87,500 (95% CI 75,485–99,515), which was nearly a 4-
fold increase. No other primary diagnosis infection code 
increased over this time period (Figure 2).
Similar rates of discharge associated with S. aureus–
related and, more speciﬁ   cally, MRSA-related infections 
per 1,000 hospitalizations were observed across all 4 US 
regions (Northeast, South, Midwest, and West; Table 2). 
Overall, the rate of S. aureus–related infections increased 
5% per year in the Northeast, 7% in the Midwest and South, 
and 8% in the West. The rate of MRSA-related infections 
in the Northeast, Midwest, and South increased 9%, 11%, 
and 12% per year, respectively. In contrast, the West had 
the lowest incidence and frequency of MRSA-related in-
fections, but the rate of MRSA-related infections increased 
18% per year. Although increases were considerable, none 
of the rates in any region was signiﬁ  cantly different in any 
year from the others at the 95% CI level.
In 2005, there were ≈11,406 S. aureus–related deaths 
(95% CI 7,609–15,203), of which 6,639 were MRSA-relat-
ed (95% CI 4,429–8,850). Since 1999, no trend was seen in 
the number of deaths. We estimated that S. aureus–related 
deaths averaged ≈10,800 per year (range 7,440–13,676) 
and MRSA-related deaths averaged ≈5,500 per year 
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Table 1. Staphylococcus aureus and methicillin-resistant S. aureus (MRSA)–related hospital discharge diagnoses, by infection site and 
year, United States 
Discharge diagnosis  1999 2000 2001 2002 2003 2004 2005
All discharges  32,131,876 31,705,672 32,652,588 33,726,612 34,738,412 34,864,168 34,667,316
S. aureus septicemias  75,125 73,206 77,998 82,813 92,247 92,785 103,300
 %  MRSA 41 45 48 49 52 54 54
 MRSA  septicemias  31,044 33,251 37,381 40,197 47,745 50,238 56,248
S. aureus pneumonias  58,833 53,692 63,759 64,294 58,511 71,275 63,185
 %  MRSA 52 54 56 58 58 59 58
 MRSA  pneumonias  30,632 29,210 35,893 37,120 33,965 41,988 36,540
Other S. aureus infections  160,612 161,614 189,715 211,310 245,971 272,873 311,442
 %  MRSA 41 44 48 50 54 58 60
 Other  MRSA  infections  65,361 71,048 90,163 106,174 132,154 158,211 185,415
Total S. aureus infections  294,570 288,512 331,472 358,417 396,729 436,933 477,927
Overall % MRSA 43 46 49 51 54 57 58
Total MRSA infections  127,036 133,510 163,437 183,491 213,864 250,438 278,203
Figure 1. Estimated methicillin-resistant Staphylococcus aureus 
(MRSA)–related hospitalization rates, United States, 1999–2005. 
Rates are no. MRSA-related discharges/1,000 hospitalizations. 
Error bars represent 95% conﬁ  dence intervals. MRSA, United States, 1999–2005
(range 3,809–7,372) (Figure 3). However, the percentage 
of  S.  aureus–related and MRSA-related hospitalizations 
that resulted in death did show a trend, a decrease from 
≈3.7% in 1999 to only 2.4% in 2005. We also calculated 
the number of deaths in which any diagnosis code was 
S. aureus–related. These calculations showed that deaths 
with an S. aureus–related discharge code increased 18% 
from 24,715 (95% CI 17,853–31,577) to 29,164 (95% CI 
21,620–36,708) from 1999 through 2005. Deaths in which 
MRSA was likely present increased >50%, from 11,240 
(95% CI 8,117–14,362) to 17,260 (95% CI 12,794–21,726) 
over the same period. However, despite the increases, the 
percentage of S. aureus–related hospitalizations that result-
ed in death decreased from 8.4% in 1999 to 6.1% in 2005, 
and the percentage of MRSA-related hospitalizations that 
resulted in death decreased from 8.8% to 6.2%.
S. aureus resistance to ampicillin/sulbactam, cepha-
lothin, and erythromycin increased 21%, 35%, and 27%, 
respectively, during the study period. Resistance to genta-
micin and trimethoprim-sulfamethoxazole decreased 76% 
and 64%, respectively. No instances of vancomycin-resis-
tant (or intermediate-resistant) S. aureus in hospitalized pa-
tients were reported.
Discussion
MRSA, a common cause of nosocomial infections, has 
emerged as an increasingly common cause of community-
associated infections (20). Our analysis extends the work of 
Kuehnert et al. (13) and quantiﬁ  es recent trends and the ef-
fect of S. aureus and MRSA on the US healthcare system.
This study focused on the effect and trends in the inci-
dence of S. aureus–related infections generally and MRSA-
related infections speciﬁ   cally. Although the number of 
hospitalizations associated with an S. aureus infection in-
creased 62% or ≈8.4% per year, the number of S. aureus 
infections resistant to methicillin increased 119% or ≈14% 
per year. In addition, although steady growth was observed 
in the incidence of S. aureus– and MRSA-related septice-
mia, pneumonia, and device-associated infections that are 
typically nosocomial, dramatic increases were observed in 
the incidence of skin and soft tissue infections that are typi-
cally community associated. We also found no trend in the 
number of deaths caused by MRSA, and a decreasing trend 
in the percentage of S. aureus– and MRSA-related hospi-
talizations that resulted in death. These results suggest a 
change in the ecology of the disease; community-associ-
ated MRSA is spreading more rapidly and possibly making 
its way into hospitals.
The indication that community-associated MRSA is 
spreading rapidly into hospitals has implications for hos-
pital and community infection control as well as empiri-
cal treatment. In hospitals, handwashing practices, which 
have been shown to be the leading intervention for limiting 
the spread of nosocomial infections, should be improved 
to meet recommended guidelines (21). Because of the in-
crease in skin and soft tissue infections, standard precau-
tions, including use of gloves, are likely warranted when 
dealing with all skin and soft tissue infections in outpatient 
clinics and acute-care facilities. Contact precautions, in-
cluding use of gowns and gloves, should be implemented 
for all wound care in acute-care facilities, and institution-
al programs to enhance antimicrobial drug stewardship 
should be implemented. Programs to increase community 
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Figure 2. Primary diagnoses of Staphylococcus aureus–related 
hospitalizations. The most frequent primary diagnosis associated 
with other S. aureus–related infections was other cellulitis and 
abscess (International Classiﬁ   cation of Diseases [ICD]-9 682), 
followed by postoperative infection (ICD-9 998.59), infections from 
an implanted device or graft (ICD-9 996), osteomyelitis (ICD-9 730), 
and diabetes mellitus (ICD-9 250). Cellulitis and abscess infections 
increased at a rate >25% per year from 1999 through 2005. No 
other primary diagnosis infection showed a major increase over this 
period. 
Table 2. Hospitalizations and rates of infections with Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) by region and 
year, United States* 
Region 1999 2000 2001 2002 2003 2004 2005
Northeast 8.42 (3.58)  8.61 (3.9)  10.01 (4.9)  10.62 (5.22)  11.25 (5.65)  11.07 (5.84)  11.59 (6.12) 
Midwest  8.53 (3.84)  9.59 (4.53)  9.8 (4.84)  9.33 (4.8)  9.65 (5.04)  11.29 (6.54)  12.47 (7.23) 
South 9.71 (4.63)  9.44 (4.68)  10.14 (5.33)  11.17 (6.15)  12.5 (7.25)  13.46 (8.21)  14.77 (9.31) 
West 9.75 (3.15)  8.33 (3.14)  10.85 (4.61)  11.05 (4.98)  11.57 (5.87)  13.75 (7.39)  15.84 (8.55) 
*Rates are no. hospitalizations with S. aureus MRSA–related discharge diagnoses/1,000 discharges. Values in parentheses are rates for MRSA. RESEARCH
awareness to control spread of infections and initiatives to 
reduce inappropriate use of antimicrobial drugs should also 
be implemented, especially in institutions that are focal in-
stitutions such as daycare centers, schools, and prisons, as 
well as in high-risk groups such as immunodeﬁ  cient per-
sons, children, and elderly persons. Clinicians should be 
aware of the magnitude of the issue and consider MRSA a 
highly likely cause of skin and soft skin tissue infections, 
even in areas where the prevalence of MRSA is believed 
to be low.
Previous hospitalization has been associated with com-
munity MRSA carriage (22), and some recent studies have 
suggested that MRSA infection rates in the community 
are positively correlated with S. aureus infection rates in 
the hospital (23,24). Although a recent study suggests that 
community-associated MRSA is causing hospital-acquired 
MRSA (25), it is unclear from our study whether commu-
nity-associated MRSA is responsible for increasing rates 
of nosocomial MRSA or the other way around. In all like-
lihood, MRSA is spreading in hospitals and communities 
and complicating efforts to prevent infections in hospital-
ized patients. Regardless, our ﬁ  ndings demonstrate that re-
cent reports of localized increases in community-acquired 
MRSA (7,26–28) are part of a larger trend of MRSA be-
coming rapidly endemic in communities all over the United 
states, emulating the wave-like pattern of emerging resis-
tance to penicillin in the middle of the 20th century (5).
Hospital-acquired infections from all causes are esti-
mated to cause >90,000 deaths per year in the United States 
and are the sixth leading cause of death nationally. Noso-
comial infections increase patient illness and the length 
of hospital stays. The direct cost has been estimated to be 
>$6 billion (inﬂ  ation adjusted) (29); costs of longer inpa-
tient visits are shared by hospitals. The increasing trend in 
hospitalizations associated with S. aureus infections has 
considerable cost implications for the healthcare system, 
including costs when community-associated infections re-
quire hospitalization and the additional expenses from as-
sociated nosocomial infections.
Antimicrobial drug–resistant infections impose even 
greater costs than susceptible infections. Several studies 
have estimated that antimicrobial drug–resistant infections 
increase death, illness, and direct costs by 30%–100% (30). 
Estimates of the excess cost of an infection with MRSA 
compared with an infection with methicillin-sensitive S. 
aureus range from ≈$3,000 to $35,000 (31–33). This sug-
gests that MRSA cost the healthcare system (patients and 
hospitals) an extra $830 million–$9.7 billion in 2005, even 
without taking into account indirect costs related to patient 
pain, illness, and time spent in the hospital.
Another important implication of our analysis is that 
the increasing incidence of MRSA in hospitalized patients, 
whether the infection was acquired in the hospital or the 
community, is likely to increase the demand for vancomy-
cin. Despite several new (daptomycin, linezolid, tigecy-
cline) and old (trimethoprim-sulfamethoxazole, clindamy-
cin) antimicrobial drugs available for treatment of MRSA 
infections, vancomycin has remained the ﬁ  rst-line drug for 
treating MRSA (12,34). This pattern has broad implications 
for the future control of MRSA as well as other pathogens. 
S. aureus infections resistant to vancomycin are already 
emerging (35), and vancomycin-resistant enterococci are 
already a major problem in hospitals. Vancomycin use 
should be restricted to methicillin-resistant S. aureus in-
fections and used only for MRSA infections in situations 
where other drugs are not appropriate.
Our analysis has some limitations. First, it was restrict-
ed to the incidence of disease associated with acute-care 
management within the hospital setting. Recent reports 
suggest that MRSA has been increasing in outpatients 
(36,37). Thus, our results represent only a part of the prob-
lem, although hospitalizations outweigh outpatient visits 
by ≈4 to 1.
Second, NHDS data enables the coding of only 7 diag-
nosis codes; hospital information systems typically include 
15–20 diagnosis codes for each admission (38). Thus, addi-
tional diagnoses in which S. aureus played a role may have 
been excluded. Errors in ICD coding when transcribing 
from doctors’ discharge summaries are another potential 
source of bias, as is the possibility that multiorgan failure, 
an end stage of sepsis, was coded as septicemia. One study 
concluded that the positive predictive value of the 038 code 
on NHDS records to predict sepsis was 88.9%–97.7%, de-
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Figure 3. Estimated hospital deaths associated with Staphylococcus 
aureus and methicillin-resistant S. aureus (MRSA), United States, 
1999–2005. Error bars represent 95% conﬁ  dence intervals. MRSA, United States, 1999–2005
pending on the criteria, and the negative predictive value 
was 80.0% (39). The authors of another study that exam-
ined whether sepsis was coded correctly on hospital bills 
concluded that strict reliance on administrative data may 
be prone to bias because only 75.4% of sepsis cases were 
accurately coded (38). Thus, our results may be an under-
estimate of the true effect, although trends are likely robust 
to coding errors.
Third, TSN data provide information concerning only 
the site of isolate collection and not the infection. Thus, 
some isolates from blood or the lung area may not be as-
sociated with septicemia or pneumonia, respectively. In ad-
dition, the code for S. aureus septicemia was given priority 
over the other more site-speciﬁ  c codes; this could have af-
fected the estimates of MRSA infections. However only a 
limited number of records had overlapping codes. 
Fourth, although the 2 data sources from TSN and 
NHDS used in this article are nationally representative, 
they may not represent a stratiﬁ  ed random sample of hos-
pitals by type and region. However, the trends are likely 
robust enough to avoid bias. In addition, the percentage of 
S. aureus isolates resistant to methicillin reported in the 
TSN database has increased similar to that reported by oth-
er national studies (Figure 4). Finally, our estimates of the 
number of hospitalizations and deaths are associated with, 
but cannot be directly attributed to, S. aureus and MRSA 
because NHDS does not report the immediate cause of 
death, and older, sicker patients are more likely to contract 
a nosocomial infection (40).
Our ﬁ  ndings suggest that S. aureus and MRSA should 
become a national priority for disease control. Possible re-
sponses include expanding national surveillance or report-
ing requirements for S. aureus and MRSA infections, more 
research to quantify the relative importance and interaction 
between community- and healthcare-associated coloniza-
tion and infection, improved investments in hospital-in-
fection control, and greater public investment to support 
research and development of an S. aureus vaccine.
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